Table 2.
Multivariate analysis of baseline characteristics between patients with and without lamivudine resistance
Adjusted P value | Adjusted OR (95% CI) | |
Male | 0.842 | 1.080 (0.506-2.307) |
Chinese | 0.343 | 2.099 (0.454-9.707) |
Mean age, yr | 0.448 | 0.989 (0.960-1.018) |
Cirrhosis | 0.977 | 1.011 (0.479-2.133) |
Baseline bilirubin, μmol/L | 0.457 | 0.996 (0.984-1.007) |
Baseline albumin, g/L | 0.108 | 0.950 (0.893-1.011) |
Baseline ALT, U/L | 0.099 | 0.997 (0.994-1.000) |
Baseline AST, U/L | 0.521 | 1.001 (0.998-1.005) |
HBeAg positive | 0.005 | 2.857 (1.383-5.903) |
Baseline log HBV DNA, IU/mL | 0.014 | 1.415 (1.073-1.865) |
Baseline abnormal ALT | 0.923 | 0.959 (0.405-2.27) |
Baseline hepatitis B virus (HBV) DNA and hepatitis B "e" antigen (HBeAg) status were independent predictors of lamivudine resistance. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.